Skip to content Skip to footer
Subscribe Now
Exclusive_Nagesh Mahanthappa_2022
EXCLUSIVE

Nagesh Mahanthappa, Interim CEO of Scholar Rock Shares Insights on Treatment Options for Spinal Muscular Atrophy

Shots: Nagesh talked about how Spinal Muscular Atrophy (SMA) is affecting people all over the world and how Scholar Rock’s treatment options are improving the lives of those living with this disease Nagesh also spoke about Scholar Rock’s lead product in SMA, apitegromab, highlighting its trial designs (TOPAZ & SAPPHIRE trials), outcomes, and real-world data…
October 3, 2022

Read more

Viewpoints_Jay Pathmanathan
VIEWPOINTS

Jay Pathmanathan, Medical Director at Beacon Biosignals Shares Insights on EEG Neurobiomarkers for the Development of Precision Medicines in Neurology

Shots: Jay spoke about the role of AI-based EEG neurobiomarkers in the development of therapies to treat neurologic diseases Jay also talked about the use of the EEG analytics platform for dose determination clinical research The interview gives an understanding of Beacon Biosignals' vision to accelerate new treatment options for neurological and psychiatric diseases Smriti: Throw…
September 27, 2022

Read more

Viewpoints_Kindra Whitlatch
VIEWPOINTS

Kindra Whitlatch, Product Applications Manager at ThermoFisher Scientific, Shares Insights on Drug Stability Testing

Shots: Kindra talked about the stability testing process and its applications in the pharmaceutical industry She also spoke about the different important parameters for stability testing and the challenges faced during this process The interview gives a deep understanding of ThermoFisher is supporting pharmaceutical and biopharmaceutical manufacturers in the drug stability testing process Smriti: Please discuss…
September 26, 2022

Read more

Top Performing Drug of 2021 – Eylea (September Edition)
INSIGHTS+

Top Performing Drug of 2021 – Eylea (September Edition)

Active Ingredient: Aflibercept Strength: 2 mg (0.05 mL) Dosage Form: Injection (intravitreal) Mechanism of Action: VEGF-A and PlGF inhibitors First Approval: US (18 Nov 2011), EU (27 Nov 2012) Revenue1 EYLEA net sales represent a significant portion of the total revenues for both Regeneron and Bayer. Both companies jointly commercialize the product Regeneron records net product sales of EYLEA in…
September 22, 2022

Read more

Spotlight Interview_Rohan (Ro) F. Hastie
CXO TALKS

Spotlight Interview with Rohan (Ro) F. Hastie, President & CEO at Metabolon

PharmaShots had its third interview for the “Spotlight- Company of the Month- Metabolon’’. The interview was with Rohan (Ro) F. Hastie, President & CEO at Metabolon where he shared insights from the journey, products, solutions, technologies, and upcoming plans of Metabolon. Metabolon develops analytical methods and software for biomarker discovery by using metabolomics. The company…
September 22, 2022

Read more

Viewpoints_Karl Bradshaw
VIEWPOINTS

Karl Bradshaw, VP of Corporate Development at Metabolon, Shares Insights on the Partnership with The University of Oxford Parkinson’s Disease Centre

Shots: Karl spoke on Metabolon’s partnership with the University of Oxford Parkinson’s Disease Centre (OPDC) to identify new metabolomic biomarkers for the advancement of Parkinson’s research  Karl also talked about the metabolomic changes which occur in Parkinson’s disease and how Metabolon will support OPDC's mission to improve research and understanding of the biology of early…
September 21, 2022

Read more

Viewpoints_Dr. Changjin Wang
VIEWPOINTS

Dr. Changjin Wang, CEO at Frontier Biotechnologies, Shares Insights on P-I Results of its Coronavirus Mpro Inhibitor

Shots: Changjin spoke about the P-I results of their lead candidate, Bofutrelvir to treat acute and long covid. The data was presented at the poster session of the 11th International Conference on ICEID, 2022 Changjin also talked about the upcoming formulations of this innovative medicine and the initiation of its BRIGHT study covering the P-II/III…
September 19, 2022

Read more

Viewpoints_Tania Small
VIEWPOINTS

Tania Small, VP, Global Medical Oncology Head, GSK, Shares Insights on Target the Future Think Tank Challenge

Shots: Tania spoke about the Target the Future Think Tank Challenge and how it will advance and address key needs in the multiple myeloma  She also talked about GSK’s collaboration with the HealthTree Foundation to provide access, education, and support for underserved communities of multiple myeloma The interview gives a profound understanding of how GSK…
September 14, 2022

Read more

ThoughtSpot_Senior Editor
THOUGHTSPOT

ILAP and its nuance vs PRIME since BREXIT

Introduction PRIME (PRIority MEdicines) EMA launched PRIME on March 07, 2016, to support the development of medicines targeting unmet medical needs. The scheme is based on enhanced interaction and early dialogue with developers of promising medicines, to optimize development plans and speed up evaluation so these medicines can reach patients faster. PRIME builds on the…
September 13, 2022

Read more

Load more